PSMA-PET/CT analysis using convolutional neural networks for PSA-based prediction of a therapeutic response in patients with metastatic castration-resistant prostate cancer (mCRPC) to 177Lu-PSMA radioligand therapy

PSMA-PET/CT analysis using convolutional neural networks for PSA-based prediction of a therapeutic response in patients with metastatic castration-resistant prostate cancer (mCRPC) to 177Lu-PSMA radioligand therapy - PSMA-PET/CT

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00024094

Enrollment

700

Registered

2023-02-17

Start date

2022-02-01

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N40 C61

Interventions

Group 1: The data to be examined (including laboratory parameters, parameters from the image data) of the respective patient are compiled anonymously immediately after the applicant has collected them

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Histologically confirmed metastatic castration-resistant prostate carcinoma (mCRPC) Patients have received at least 2 cycles of 177Lu-PSMA radioligand therapy

Exclusion criteria

Exclusion criteria: • Lack of information on the clinical course • Missing serum PSA levels • Missing image datas

Design outcomes

Primary

Measure	Time frame
Reduction of the serum PSA value after therapy by more than 50% (= responder) or by less than 50% (= non-responder)	—

Secondary

Measure	Time frame
Sensitivity, specificity, positive predictive value and negative predictive value of the convolutional neural network for predicting a therapy response	—

Countries

Germany

Contacts

Public ContactClemens Cyran

LMU München

clemens.cyran@med.uni-muenchen.de+4989440076642

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026